KRAS and cancer: Similarly, in a model of pancreatic ductal adenocarcinoma, the IGF-1R tyrosine kinase inhibitor linsitinib was employed to target and eliminate residual cancer cells that had persistently survived despite the ablation of key oncogenes such as c-MYC or K-RAS (198).